STOCK TITAN

Insider sale notice: Oculus Therapeutics (NASDAQ: OCUL) files Form 144 for vested shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Oculus Therapeutics (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.

The filing names Pravin Dugel and lists prior sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61.

Positive

  • None.

Negative

  • None.

Insights

Form 144 notices a proposed resale of vested restricted shares under a registered plan.

Form 144 is a statutory notice of an intended sale under Rule 144; this filing identifies proposed sales of common stock on 02/22/2026 tied to restricted stock vesting under a registered plan.

Cash‑flow treatment and placement method are not stated in the excerpt; subsequent trade reports or a Form 4/transaction filing would confirm execution details.

Insider disposals reported recently, with multiple past‑quarter sales disclosed.

The excerpt lists prior dispositions by Pravin Dugel: 124,882 shares on 02/12/2026 and 19,530 shares on 11/24/2025, with proceeds shown in dollars. These are explicit transaction records, not company operational metrics.

Timing and execution of the 02/22/2026 sales relate to vesting; future filings may state whether sales occurred and under what method.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does OCUL's Form 144 filed on 02/22/2026 report?

It reports proposed sales of common stock tied to restricted stock vesting under a registered plan on 02/22/2026. The filing names the insider and lists prior sales with share counts and gross proceeds.

Who is the insider listed in OCUL's Form 144?

The filing names Pravin Dugel at an address in Bedford, MA. It associates him with prior sales of common shares reported on 02/12/2026 and 11/24/2025.

How many shares did Pravin Dugel sell recently according to the filing?

The excerpt shows sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61. These are reported gross proceeds.

Does the Form 144 confirm the 02/22/2026 sale executed?

No. Form 144 is a notice of proposed sale tied to vesting on 02/22/2026. Execution and method of sale are not confirmed in this excerpt and would appear in later trade‑reporting filings if sold.

Are proceeds from the proposed sales paid to the company (OCUL)?

The excerpt does not state proceeds treatment. Listed prior sales show gross proceeds to the selling person; the Form 144 itself does not indicate company receipt of proceeds in this excerpt.
Ocular Therapeut

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

1.83B
210.92M
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD